Literature DB >> 8709259

Human adenovirus-specific CD8+ T-cell responses are not inhibited by E3-19K in the presence of gamma interferon.

P Flomenberg1, V Piaskowski, R L Truitt, J T Casper.   

Abstract

Adenovirus has considerable potential as a gene therapy vector, but recent animal data suggest that transduced cells are destroyed by adenovirus-specific cytotoxic T-lymphocyte (CTL) responses. Therefore, it will be important to develop strategies to evade adenovirus-specific CTL responses in humans. As a first step, an assay was developed to detect and characterize human CTLs directed against adenovirus. Adenovirus-specific CTL responses were demonstrated to be present in four of five healthy adults by in vitro stimulation of peripheral blood mononuclear cells with autologous fibroblasts infected with the adenovirus type 2 (Ad2) E3 deletion mutant Ad2+ND1. Killing by adenovirus-specific CTLs was major histocompatibility complex class I restricted and was documented to be mediated by CD8+ T cells. Wild-type-Ad2-infected cells were poor CTL targets compared with cells infected with the E3 deletion mutant because of the expression of E3-19K, an early viral glycoprotein which prevents transport of major histocompatibility complex class I antigens out of the endoplasmic reticulum to the cell surface. However, preincubation of targets with gamma interferon resulted in enhanced killing of wild-type-Ad2-infected cells, to levels comparable to those obtained with Ad2+ ND1-infected cells. Radioimmunoprecipitation analysis revealed that gamma interferon not only increased the synthesis of class I antigens but also allowed excess molecules to escape from the endoplasmic reticulum. It is concluded that E3-19K expression in adenovirus-infected cells inhibits human CTL recognition in vitro but that gamma interferon may help overcome the E3-19K effect during acute infection in vivo.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8709259      PMCID: PMC190657          DOI: 10.1128/JVI.70.9.6314-6322.1996

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  47 in total

1.  Eradication of adenovirus E1-induced tumors by E1A-specific cytotoxic T lymphocytes.

Authors:  W M Kast; R Offringa; P J Peters; A C Voordouw; R H Meloen; A J van der Eb; C J Melief
Journal:  Cell       Date:  1989-11-17       Impact factor: 41.582

2.  MHC class II structure, occupancy and surface expression determined by post-endoplasmic reticulum antigen binding.

Authors:  R N Germain; L R Hendrix
Journal:  Nature       Date:  1991-09-12       Impact factor: 49.962

3.  Mouse anti-adenovirus cytotoxic T lymphocytes. Inhibition of lysis by E3 gp19K but not E3 14.7K.

Authors:  F C Rawle; A E Tollefson; W S Wold; L R Gooding
Journal:  J Immunol       Date:  1989-09-15       Impact factor: 5.422

4.  A 6700 MW membrane protein is encoded by region E3 of adenovirus type 2.

Authors:  J Wilson-Rawls; S K Saha; P Krajcsi; A E Tollefson; L R Gooding; W S Wold
Journal:  Virology       Date:  1990-09       Impact factor: 3.616

5.  Disseminated adenovirus infection with hepatic necrosis in patients with human immunodeficiency virus infection and other immunodeficiency states.

Authors:  L R Krilov; L G Rubin; M Frogel; E Gloster; K Ni; M Kaplan; S M Lipson
Journal:  Rev Infect Dis       Date:  1990 Mar-Apr

6.  Class I MHC-restricted cytotoxic T lymphocyte recognition of cells infected with human cytomegalovirus does not require endogenous viral gene expression.

Authors:  S R Riddell; M Rabin; A P Geballe; W J Britt; P D Greenberg
Journal:  J Immunol       Date:  1991-04-15       Impact factor: 5.422

7.  Specificity of the mouse cytotoxic T lymphocyte response to adenovirus 5. E1A is immunodominant in H-2b, but not in H-2d or H-2k mice.

Authors:  F C Rawle; B B Knowles; R P Ricciardi; V Brahmacheri; P Duerksen-Hughes; W S Wold; L R Gooding
Journal:  J Immunol       Date:  1991-06-01       Impact factor: 5.422

8.  Differential effect of adenovirus 2 E3/19K glycoprotein on the expression of H-2Kb and H-2Db class I antigens and H-2Kb- and H-2Db-restricted SV40-specific CTL-mediated lysis.

Authors:  Y Tanaka; S S Tevethia
Journal:  Virology       Date:  1988-08       Impact factor: 3.616

9.  Retention of adenovirus E19 glycoprotein in the endoplasmic reticulum is essential to its ability to block antigen presentation.

Authors:  J H Cox; J R Bennink; J W Yewdell
Journal:  J Exp Med       Date:  1991-12-01       Impact factor: 14.307

10.  Adenovirus-induced release of epidermal growth factor and pseudomonas toxin into the cytosol of KB cells during receptor-mediated endocytosis.

Authors:  D J FitzGerald; R Padmanabhan; I Pastan; M C Willingham
Journal:  Cell       Date:  1983-02       Impact factor: 66.850

View more
  18 in total

1.  MHC class I-subversive gene functions of cytomegalovirus and their regulation by interferons-an intricate balance.

Authors:  C Benz; H Hengel
Journal:  Virus Genes       Date:  2000       Impact factor: 2.332

2.  Determinants of the endoplasmic reticulum (ER) lumenal-domain of the adenovirus serotype 2 E3-19K protein for association with and ER-retention of major histocompatibility complex class I molecules.

Authors:  Jie Fu; Marlene Bouvier
Journal:  Mol Immunol       Date:  2010-11-20       Impact factor: 4.407

3.  Adenovirus E3/19K promotes evasion of NK cell recognition by intracellular sequestration of the NKG2D ligands major histocompatibility complex class I chain-related proteins A and B.

Authors:  Brian P McSharry; Hans-Gerhard Burgert; Douglas P Owen; Richard J Stanton; Virginie Prod'homme; Martina Sester; Katja Koebernick; Veronika Groh; Thomas Spies; Steven Cox; Ann-Margaret Little; Eddie C Y Wang; Peter Tomasec; Gavin W G Wilkinson
Journal:  J Virol       Date:  2008-02-20       Impact factor: 5.103

4.  Immune response to recombinant adenovirus in humans: capsid components from viral input are targets for vector-specific cytotoxic T lymphocytes.

Authors:  V Molinier-Frenkel; H Gahery-Segard; M Mehtali; C Le Boulaire; S Ribault; P Boulanger; T Tursz; J G Guillet; F Farace
Journal:  J Virol       Date:  2000-08       Impact factor: 5.103

5.  Adenovirus E3-19K proteins of different serotypes and subgroups have similar, yet distinct, immunomodulatory functions toward major histocompatibility class I molecules.

Authors:  Jie Fu; Lenong Li; Marlene Bouvier
Journal:  J Biol Chem       Date:  2011-03-25       Impact factor: 5.157

6.  Phase I trial of recombinant adenovirus gene transfer in lung cancer. Longitudinal study of the immune responses to transgene and viral products.

Authors:  H Gahéry-Ségard; V Molinier-Frenkel; C Le Boulaire; P Saulnier; P Opolon; R Lengagne; E Gautier; A Le Cesne; L Zitvogel; A Venet; C Schatz; M Courtney; T Le Chevalier; T Tursz; J G Guillet; F Farace
Journal:  J Clin Invest       Date:  1997-11-01       Impact factor: 14.808

Review 7.  Immune evasion by adenoviruses: a window into host-virus adaptation.

Authors:  Edson R A Oliveira; Marlene Bouvier
Journal:  FEBS Lett       Date:  2019-12-05       Impact factor: 4.124

8.  Discovery of small molecule inhibitors of adenovirus by disrupting E3-19K/HLA-A2 interactions.

Authors:  Jinhong Ren; Nikita R Dsouza; Hui Deng; Hyun Lee; Marlene Bouvier; Michael E Johnson
Journal:  Bioorg Med Chem Lett       Date:  2018-07-29       Impact factor: 2.823

Review 9.  Strategies to overcome host immunity to adenovirus vectors in vaccine development.

Authors:  Erin E Thacker; Laura Timares; Qiana L Matthews
Journal:  Expert Rev Vaccines       Date:  2009-06       Impact factor: 5.217

10.  Evaluation of cross-reactive cell-mediated immune responses among human, bovine and porcine adenoviruses.

Authors:  A Sharma; M Tandon; Y S Ahi; D S Bangari; R Vemulapalli; S K Mittal
Journal:  Gene Ther       Date:  2010-02-18       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.